Medical network, June 15, June 14, the ministry of commerce website published the 2016 medicine circulation industry run statistical analysis report, to our country medicine circulation industry as a whole scale, sales of pharmaceutical wholesale and retail enterprises, pharmaceutical logistics distribution and statistical analysis was made on medical electrical business operations, and so on and so forth, and analyses the characteristics and trend of development of the industry.
The report pointed out that, along with the implementation of the strategy of "healthy China" and "much starker choices-and graver consequences-in" deepening the reform of medical health system, medicine circulation industry development on the new starting point. The total sales of seven categories of pharmaceutical products in the whole year totaled 18.393 billion yuan, a year-on-year increase of 10.4%, a year-on-year increase of 0.2 percentage points. Among them, the pharmaceutical retail market was 367.9 billion yuan, excluding non-comparable factors, up 9.5 percent year on year and 0.9 percentage points higher than the previous year.
The report argues that medicine circulation industry in 2016 to run the following features: general pharmaceutical wholesale enterprises sales growth is slowing but concentration increased slightly, the rate of drug retail chain enterprise sales have rebounded and continuous improvement, a new mode of medical electrical contractor, pharmaceutical logistics operation efficiency and service function of continued ascension.
The report predicted that as the implementation of the reform measures, medicine circulation industry development in 2017 will face new opportunities and challenges, accelerate the conversion of adjustment and industry development mode and pattern of capital market integration power of the enterprise, increased rapidly escalate pharmaceutical supply chain management services, medicine, electricity cross-border integration process continues to advance, drug retail business innovation, industry growing infrastructure role.
Operational statistical analysis report (2016)
General situation of the development of pharmaceutical circulation industry
In 2016 is "much starker choices-and graver consequences-in" the start of the implementation of the national medicine circulation industry development planning, is the country to deepen structural reform in the first year of supply side, has entered a new round of reform of "3 d linkage" accelerating period. Countries have issued the "healthy China 2030" planning outline ", "" much starker choices-and graver consequences-in" during deepening medical and health system reform plan ", "national medicine circulation industry development planning (2016-2020) and a series of policy document. Under this background, the medicine circulation industry to actively implement the reform policy requirements, trying to explore innovative development thinking, improve the level of medicine supply chain management, promote the pharmaceutical service and health management service mode upgrade, speed up cross-border integration of resources, industry development on the new starting point.
(1) the overall scale
The market for drug circulation rose steadily in 2016, with a slight pick-up in growth. Ministry of commerce of drug circulation statistics system, according to national pharmaceutical seven class total sales of 1.8393 trillion yuan (sales tax value), excluding factors than year-on-year growth of 10.4%, grew up 0.2% from a year earlier. Among them, the pharmaceutical retail market was 367.9 billion yuan, excluding non-comparable factors, up 9.5 percent year on year and 0.9 percentage points higher than the previous year.
As of the end of November 2016, there were 12,975 wholesale pharmaceutical enterprises nationwide. There were 5,609 pharmaceutical retail chains and 220,703 outlets. Retail pharmacies have 226,331 pharmacies and 4,47,034 retail pharmacies. (source: state food and drug administration)
(2) enterprise benefit
In 2016, the total revenue of pharmaceutical companies in the country was 13.99.4 billion yuan, a year-on-year increase of 11.6%, a year-on-year increase of 0.7 percentage points. Total profits totaled 32.2 billion yuan, excluding non-comparable factors, up 10.9% year on year, up 0.3 percentage points from a year ago. Average gross margin was 7.0%, up 0.1 percentage points from a year earlier. The average cost was 5.2 percent, down 0.2 percentage points from a year earlier. The average profit margin was 1.8%, up 0.1 percentage points from a year earlier. The net profit margin was 1.5%, up 0.1 percentage points from a year earlier.
(3) sales category and channel structure
According to the sales category classification, western medicine (including chemical drug preparations, chemical pharmaceuticals and its preparations, radioactive drugs, vaccines, blood products, and serum in the diagnosis of drug, etc., but does not include chemical reagent, etc.) sales dominant, accounted for 74.4% of the total amount of seven class of pharmaceutical sales, followed by proprietary Chinese medicine class (15.0%), traditional Chinese medicine class accounted for 3.0%, medical equipment class (3.3%), chemical class (1.2%), glassware class accounted for 0.1%, other classes (3.0%).
According to association of Chinese pharmaceutical business of typical sample urban retail pharmacies category sales statistics, 2016, retail drug stores in drug class of dominant, accounted for 80.2% of total retail sales, which accounted for 46.0% of western medicine (chemical medicine (38.7%) and biological products (7.3%), proprietary Chinese medicine accounted for 27.3%, Chinese medicine yinpian accounted for 6.9%; The drug sales accounted for 19.8%, with food (including health food) accounted for 11.6%, medical apparatus and instruments (including nursing homes) accounted for 5.7%, and cosmeceuticals, daily necessities and other commodities that three kinds of total accounted for less than 3.0%.
 、
按銷售渠道分類，2016年對生產(chǎn)企業(yè)銷售額60億元，占銷售總額的0.3%；對批發(fā)企業(yè)銷售額7520億元，占銷售總額的40.9%，同比下降0.9個百分點(diǎn)；對終端銷售額10813億元，占銷售總額的58.8%，同比上升0.6個百分點(diǎn)。其中，對醫(yī)療機(jī)構(gòu)銷售額7673億元，占終端銷售額的71.0%；對零售終端和居民零售銷售額3141億元，占終端銷售額的29.0%。
（四）銷售區(qū)域結(jié)構(gòu)
2016年，全國六大區(qū)域銷售額占全國銷售總額的比重分別為：華東37.4%、華北16.2%、中南23.7%、西南13.0%、東北5.1%、西北4.6%。其中，華東、華北、中南三大區(qū)域銷售額占到全國銷售總額的77.3%，同比上升0.1個百分點(diǎn)。
三大經(jīng)濟(jì)區(qū)藥品銷售額占全國銷售總額的比重分別為：京津冀經(jīng)濟(jì)區(qū)13.8%、長江三角洲經(jīng)濟(jì)區(qū)22.8%、珠江三角洲經(jīng)濟(jì)區(qū)8.7%。
2016年銷售額居前10位的省市依次為：廣東、北京、上海、浙江、江蘇、安徽、山東、河南、四川、云南。上述省市銷售額占全國銷售總額的64.2%，同比上升0.4個百分點(diǎn)。
（五）所有制結(jié)構(gòu)
在全國藥品流通直報企業(yè)中，國有及國有控股藥品流通企業(yè)主營業(yè)務(wù)收入8489億元，占直報企業(yè)主營業(yè)務(wù)總收入的60.7%；實(shí)現(xiàn)利潤168億元，占直報企業(yè)利潤總額的52.2%。股份制企業(yè)主營業(yè)務(wù)收入3871億元，占直報企業(yè)主營業(yè)務(wù)總收入的27.6%；實(shí)現(xiàn)利潤114億元，占直報企業(yè)利潤總額的35.5%。
(6) medical and logistics distribution
According to incomplete statistics, in 2016 the national pharmaceutical logistics for enterprises (192), no sales tax 192 yuan, which has the qualifications of independent legal representive.it is also the enterprise sales accounted for 83.0%. More than 1.22 million customers were delivered. There are 674 logistics centers, and the warehouse area is about 7.23 million square meters. Among them, the room temperature is 26.0%, the cooler is 71.8% and the refrigerator is 2.2%. The warehouse storage standard pallet number is approximately 2790 thousand, and the tray number is about 1.8million. There are 13534 professional transport vehicles, including 11.1 percent of refrigerated vehicles and 2.2 percent of special drug vehicles. Basic medicines account for 88.8% of distribution and 11.2% of foreign distribution.
(7) the situation of medical and electronic commerce
According to incomplete statistics, in 2016 medical electrical business for enterprises (the amount of data: only B2B business enterprise for 40, only B2C business enterprise for 47, both B2B and B2C business enterprise for six) total sales of 61.2 billion yuan. Of these, business-to-business (business-to-business) sales totaled 57.6 billion yuan, accounting for 94.2% of the total sales of pharmaceutical e-commerce companies. B2C (business-to-consumer) business has sales of 3.6 billion yuan, or 5.8 percent of the total sales of pharmaceutical e-commerce. The mobile side of the B2B business is 4.3 percent, while the mobile side of the B2C business is 46.0%. The total number of orders was 4305,000, of which the number of B2B orders was 16.32 million, and the order conversion rate was 96.7%. The number of B2C orders was 26,300, and the order conversion rate was 86.3 percent. B2B sites have 270,000 active users, with average customers at 3,652 yuan, and 791 on average. The B2C site has 11.2 million active users, with an average of 148 yuan per customer and 11 on average. The B2B sunrise inventory was 98.4%, and the B2C sunrise library was 96.5%. The B2B business cost 16.5%, the B2C business rate is 22.2%, all well above the industry average. B2B and B2C sales structure difference is more apparent, B2B business mainly in western medicine, and other classes in the B2C business (including health care category, cosmetics and personal care products and adult supplies, family planning, etc.) of the highest.
 
(8) the listing of enterprises
In 2016, there are two new companies listed in the pharmaceutical circulation industry, respectively. Currently, the 23 listed companies in the pharmaceutical circulation industry total 824.6 billion yuan in 2016, up 15.5 percent year on year. The last trading day of the year was a total of 462.7 billion yuan, with an average market value of 20.1 billion yuan. Companies that the market value of 10 billion yuan of above 16, sinopharm, medicine, China resources medicine, Shanghai east China pharmaceutical, kyushu, its consistent, rui kang medicine, Chinese medicine, tongji hall, haiwang biology, share, common people, liuzhou medicine, one hall, yi feng pharmacy and fine things don, sinopharm and Shanghai pharma and CRC value in medicine, more than 40 billion yuan. A total of 86 outbound investment activities disclosed by companies listed in the pharmaceutical circulation industry have been disclosed in 2016, involving a total of 12.5 billion yuan.
(9) registration of licensed pharmacists
According to the state administration of food and drug administration, the total number of registered pharmacists in the country reached 342,109 as of December 31, 2016, an increase of 84,476 people. The registered pharmacist registration rate reached 52.7 percent, down 9.6 percent year on year. The number of registered pharmacists for every 10,000 people in the country was 2.5, up 31.6 percent year on year.
(10) social and economic contribution
According to the national bureau of statistics, in 2016 the national total retail sales of social consumer goods is 33.2 trillion yuan, the added value of the third industry is 38.4 trillion yuan, total annual sales of medicine circulation industry accounted for 4.8% of the added value of the third industry, fell 0.1% year on year. The retail sales accounted for 1.1 percent of the total retail sales of consumer goods, and were unchanged from the previous year.
In 2016, the total amount of national drug circulation in the country was 7349 million yuan, or 9.9% year-on-year. The industry employs about 5.45 million people.
The main characteristics of the operation of the pharmaceutical circulation industry
(1) the sales growth of drug wholesalers has slowed, and concentration has risen slightly
In terms of sales growth, the sales growth of large drug wholesalers is higher than the industry average, but it has slowed. In 2016, the top 100 companies in the pharmaceutical wholesale business were up 14.0 percent from the year before, a 1.6 percent drop in growth. Among them, four of the country's leading businesses grew 12.2 per cent year-on-year, down 7.5 percentage points from a year earlier. The business revenue of 15 regional leading enterprises increased by 17.6% year on year and 5.2 percentage points.
In terms of market share, the concentration of pharmaceutical wholesale industry has been further improved. In 2016, the top 100 companies accounted for 70.9 percent of the country's total pharmaceutical market, up 2.0 percent year on year. Among them, four national champions accounted for 37.4% of the total pharmaceutical market in the same period, up half a percentage point from a year earlier. The main business income of 15 regional leading enterprises accounted for 18.4% of the total pharmaceutical market in the same period, up 1.1 percentage points from the year before. The last group of companies in the ranking grew from 1.15 billion yuan in 2015 to 1.24 billion yuan in 2016.
As the reform policies have been gradually implemented, the consolidation of the pharmaceutical wholesale industry has accelerated. Data show that in the market has a certain scale of pharmaceutical wholesale enterprises are actively layout, efforts to improve its management ability, operation ability and management ability, target stride forward to the network, intensive and informationization, promote the construction of modern medicine circulation system.
(2) sales of pharmaceutical and retail enterprises have picked up, and the rate of linkage has continued to rise
In 2016, the retail sales of the pharmaceutical market were 367.9 billion yuan, up by 9.5 percent year on year, and the growth rate was 0.9 percentage points higher than the previous year, maintaining steady growth. With the development of national health reform and health policies, new development opportunities are emerging in the retail market. Drug retailers are developing the development direction of the big health industry, taking the opportunity of healthcare reform, innovating service model and expanding value-added services. Some enterprises have promoted innovation in the industry in various forms, such as online pharmacy, traditional Chinese medicine hall, pharmacy (beauty), brand store, DTP pharmacy, pharmacy federation, etc. Separate parts enterprises to participate in grassroots medical institutions "medicine", "hierarchical diagnosis and treatment process, to carry out the community pharmacy matchs outside point construction, the prescription and medicine (library) managed shop business cooperation.
In 2016, the big retail chains, represented by listed companies, were merging faster and the retail chain rate continued to rise. By November 2016, the retail chain had been 49.4%, up 3.7 percentage points from a year earlier. The total number of retail outlets in the top 100 retail stores reached 54391, accounting for 12.2% of the total retail stores in the country. Sales totaled 107 billion yuan, accounting for 29.1 percent of the total retail market, up 0.3 percentage points from a year earlier. Among them, the total sales of seven national champions totaled 4.75 billion yuan, accounting for 12.9 percent of the total national retail market, up 0.8 percentage points year-on-year. The total sales of 14 regional retail chains totaled 29.2 billion yuan, accounting for 7.9% of the national retail market, down 0.1 percentage points year-on-year. The last group of companies in the ranking grew from 110 million yuan in 2015 to 140 million yuan in 2016. According to the data, the market share of national champions increased slightly from the previous year, and the market share of regional retail chains declined slightly. This further reflects the tendency of market sales to focus on large chains.
(3) medical and e-commerce companies have become important development patterns in the pharmaceutical circulation industry
In 2016, the Internet companies and the Internet companies outside the industry have shown great confidence in the development of "Internet plus". Drug sales in the online pharmacies were up 50 per cent year on year (data source: CFDA southern pharmaceutical economic research institute). All kinds of new type of medical electrical business model, to B2C, B2B gradually O2O (online to offline) model transformation, such as traditional commercial trade gradually to the modern comprehensive service transformation. As countries accused of using Internet technology to build cooperation with hospitals in tianjin new service mode, from PC to mobile terminal, lead for electricity differentiation, diversification development direction; Kyushu through establishing good pharmacists pharmaceutical health mall to carry out the entire network marketing, service models including the integration of online channel mode, O2O last mile delivery service mode and the Internet mode "sought treatment" service mode, slow disease management mode. At the beginning of 2017, the state council announced the cancellation of the approval of B and C. This means that legitimate pharmaceutical companies are free to develop B2B, B2C businesses for Internet drugs, and the development of pharmaceutical e-commerce is coming in spring.
(4) the operational efficiency of medical logistics and the continuous improvement of service function
Modern logistics technology has greatly improved the operating efficiency of drug circulation enterprises, reduced the management cost, and effectively promoted the development of supply chain.
According to incomplete statistics, the number of modern pharmaceutical logistics enterprises with warehouse management systems accounted for 74.5%, accounted for 93.8% of temperature and humidity automatic monitoring system, has accounted for 85.4% of the order management system, with digital picking system (DPS) accounted for 50.5%, has accounted for 55.2% of radio frequency identification (RFID) system, has the warehouse control system (WCS) accounted for 55.7%, with transportation management system (TMS) accounted for 53.6%, with the traceability of temperature and humidity monitoring system accounted for 84.9%, with customer relationship management system (CRM) accounted for 49.5%, with the owner management system (TPL) accounted for 45.3%. The cost of logistics account for three expenses (operating expenses, administrative expenses and financial expenses) of the pharmaceutical logistics enterprise is 8.9%, accounting for 15.1% of the operating expenses. The ratio of the balance of accounts to the delivery rate of the goods reached 98.5%, and the error rate of the warehouse was 0.1%.
In addition, some large drug distribution enterprises have strengthened international exchanges and cooperation, and actively promoted industry services and international contacts. Such as Huadong Medicine Co., ltd. in the business concept, organization structure and business model for reform, introduction of the Internet thinking, in line with international standards, the development characteristics of big health sector; The western medicine group in collaboration with IBM, choose LinuxONE of IBM mainframe, build medical strongest brain "bodhi medical cloud platform", in support of Qingdao municipal hospital (group) "in the" Internet of things cloud hospital; Melt penetration electrical contractor to launch a big health industry "innovation union", and deeply involved in Lima, Peru "2016 APEC meeting", fully open big global innovation and practice in the field of ecological health.
Development trend of drug circulation industry
2017 is a crucial year for deepening reform of the medical and health care system and advancing supply-side structural reform. In the "healthy China 2030" planning outline ", "" much starker choices-and graver consequences-in" during the deepening medical and health system reform plan, the state council general office on further reform and improve the pharmaceutical production circulation use policy several opinions and the printing on drug procurement in the public medical institutions in the implementation of the implementation of the "two votes" opinion (trial) notice, under the guidance of guiding policy documents such as the reform measures will fully implementing, industry development is facing new opportunities and challenges.
(1) accelerating the transformation of the development pattern of the pharmaceutical circulation industry
"Much starker choices-and graver consequences-in" period, people's demand for health service and health care will increase dramatically, medicines, health products and health services market scale will accelerate growth, has provided a broad space for the drug circulation industry development. As to promote coordinated development of the new urbanization and modern service industry the national policy and implementation of the medicine circulation industry will gradually from the consumption of resource allocation model of capital market leading pattern of resource allocation. In the national medicine circulation industry development planning (2016-2020), under the lead of the industry restructuring of the formats will continue to accelerate, with retail business integration development will become mainstream, national, regional and drug retail brand enterprise will be listed in restructuring. Innovative companies based on Internet technology will be able to use the capital market for further development. At the same time, the medicine circulation industry also faces the challenge of new pattern, new forms and new technology, market competition will be more fully, the enterprise management and cost control ability will be sorely tested. Medicine circulation enterprises in a timely manner to find efficient way of innovation to upgrade, bigger and stronger, "for short, restructuring", gradually from extensive operation to intensive and quality benefits of innovative business transformation.
(2) the pattern of the pharmaceutical distribution industry has been comprehensively adjusted
At present, the "medical treatment, health care, medical 3 d linkage" comprehensive reform has entered into deep waters, along with relevant supporting policies closely, refining the reform direction of clarity. Hierarchical diagnosis and treatment, the modern hospital management, universal health care, drug supply security and comprehensive supervision system construction will be the important breakthrough direction of the next step to deepen reform, generic consistency evaluation, family doctors and medicine circulation "two votes" total payment methods, health care reform, health care, control and so on various policy measures, covered from drug supply side to the important link of the demand side, will gradually break the existing drugs circulation value chain, speed up the medicine circulation industry evolution. Especially the implementation of the policy of "two votes", will slash drug circulation, accelerate the industry reshuffle process, make the high credibility, strong normative, terminal wide coverage, and strong sales ability of large medicine circulation enterprises market share rapidly improve, constantly improve the industry concentration, and gradually reversed transmission drug retail, logistics, electricity industry to accelerate the intensification, informatization, standardization and finally realize the comprehensive of industry structure adjustment.
(3) the capital market has increased the power of integration of enterprises
During the 13th five-year plan period, the pharmaceutical circulation enterprises will accelerate integration under the help of the capital markets, and will continue to achieve strong and strong coalitions. The annual report from listed companies shows that drug companies are more active in mergers and acquisitions. For example, in 2016, it has completed the acquisition and acquisition arrangement of more than 20 provinces and cities across the country.
At the same time, retail chains will be the target of a competing company. At present, the pharmaceutical retail industry concentration degree is low, listings, with less than wholesaling is listed in the early stage of development, the future of pharmaceutical retail enterprises mergers and acquisitions will enter the stage of rapid development. As many listed their retail chain enterprises, expansion of outlets, small and medium-sized monomer pharmacies will actively or passively accept shuffling, industry consolidation will aggravate, retail chain pharmacy rate will continue to improve.
In several types of fundraising, short-term borrowing is still the main way to raise money for listed companies. Because of the long queue time for ipos, the new three-board listing will be a growing way for drug companies to raise money.
(4) medical supply chain management services were upgraded rapidly
As reform New Deal releasing and the rapid development of industry information construction, medicine circulation enterprises will gradually using the global supply chain thinking, use of the Internet of things, chain blocks, such as technology, construction supply chain integration management platform, get through the gap of logistics, cash flow and information flow, at the same time to provide supply chain upstream and downstream market development, price negotiation, online payment, financial support and other value-added services and integrated solutions, use technologies such as cloud computing, big data mining the value of data, auxiliary enterprises and business decision to end customer, fundamentally solve the problem of information island, so as to improve logistics efficiency, reduce operating costs. Such as national medicine logistics to create a "flying" cloud platform, supply chain management by operating service system, logistics service system and data service system to realize the demand forecasting, distributed inbound and outbound strategy and automatic replenishment, and other functions.
At the same time, the medicine circulation enterprises with suitable abundant, China postal third party logistics enterprise cooperation and promote medical logistics resources, promote the optimization of supply chain, improve the efficiency of drug distribution. Medicine circulation enterprises will open sharing, win-win cooperation, relying on the Internet to build efficient ecological wisdom logistics system, build a digital, standardization, informationization, open, Internet platform, co-ordinated pharmaceutical logistics information sharing system, to the excellent medical service supply chain transformation.
(5) the process of cross-border integration of pharmaceutical and telecommunications companies continued to advance
National "Internet +" policy, the development of the medical and health system reform, the formation of "great health" consumer concept, the application of network information technology, to medical electrical business development to create a good policy, market and technology environment, the industry will usher in rapid development. In the medicine circulation enterprises from traditional distributors to supply chain service providers in the process of transformation, medicine, electricity enterprises will rely on the Internet, the Internet of things, big data, cloud computing and other advanced technology, for the industry to provide value-added services of first-mover advantage. "Prescription + + electronic prescription health online payment" tripartite model of information sharing or will be the next drug retail business growth, and differentiation positioning will also determine the development of enterprises can be recognised by the market and rapid growth. As part of the medicine circulation enterprises development guided by the demands of the c-terminal C2B2M mode of consumer to dealers and manufacturers, part of the enterprise and the medicine O2O platform (such as JPM medicine, fast delivery, good medicine, etc.), traffic resource platform to achieve the Internet to make use of the transformation. At the same time, the medical electric business enterprise to integrate supply chain upstream and downstream resources, take advantage of the Internet, big data information technology, based on B2B, B2C, O2O e-commerce platform offline entities pharmacy and drug distribution network, improve the patients with drug supply security and health service system, realize the "net book store take", "net book store send" online linkage, such as the goal, to accelerate the process of online fusion.
(6) the retail operation of drugs is constantly innovating
In 2017, the drug retail sector will enter the year of opportunity. With the development of public hospital reform and the introduction of supporting policies such as health care, the reform trend of "medical separation" is becoming more and more obvious. Medical institutions and health care institutions and retail pharmacy information sharing pilot and retail pharmacies classification grading management trial will provide important opportunities for the development of pharmaceutical retail industry and retail pharmacies to undertake the medical institutions with the prescription work is about to begin.
At the same time, along with the national macroeconomic growth is slowing, drugs "zero rate" policy of medical institutions, drug retail sales growth will slow, profitability may decline. In this context, fusion innovation and transformation upgrade are the only way to develop. The development of new forms, new products, create a new environment, use of new technologies, to try new mode and new marketing, to expand new area will become the mainstream trend, standardization and specialization management will become the inevitable choice, consumer experience centered health counseling, medication guide, data testing, auxiliary diagnosis and other professional pharmaceutical affairs service will create more "new retail" model.
(7) the role of the industry is becoming more and more important
During the 13th five-year plan period, the development of drug circulation industry entered a new turning period. Facing the complex and changeful market environment, to strengthen the construction of industry based data will drive the industry people, logistics, capital, information resources to fully mix, enhance the core competitiveness, enterprise to the healthy and orderly development of medicine circulation industry to provide strong support. Medicine circulation enterprises to establish cooperation relationship with the competent department of industry, association, unified medicine circulation encoding rules, make standard of electronic data interaction, the primary database construction industry, to build a comprehensive business management platform, improve the efficiency of information interaction between the enterprise and supply chain upstream and downstream, reduce the repeated input of industry of social resources. At the same time, the value of data information is mined, the system of data is built, the brand effect is created, and the social value is created.
In the current increasingly fierce competition in the industry environment, medicine circulation enterprises will continue to enhance the level of human resource management, attaches great importance to the cultivation of talents and staff career planning, strengthen the team building, build knowledge, creative talent growth enterprise culture, cultivating inter-disciplinary talent across borders and all kinds of professional talents. At the same time, a comprehensive talent with medical, nursing, nursing and health management background is pre-cultivated or actively introduced, which is a good foundation for the sustainable development of enterprises.
Appendix > > >
     |
